Invasive mold infections in Thailand, Taiwan, India, China and Singapore
July 27 2017
Invasive mould infection (IMI) is a term for a large spectrum of emerging invasive diseases such as aspergillosis, zygomycosis, phaeohyphomycosis, or other mould infections. A recent study of the epidemiological and clinical characteristics of 155 IMI cases among Asian patients (Thailand, Taiwan, India, China and Singapore) has just been published by Dr Porpon Rotjanapan from Ramathibodi Hospital, Bangkok, Thailand and colleagues. In retrospective data from 2012 of 155 IMI cases found an incidence rate between 0.024 and 0.236 per 1,000 patient-days in hospital.
Major trial shows flucytosine a critical component of reducing deaths from cryptococcal meningitis
July 24 2017
At the International AIDS Society conference in Paris today, Sile Molloy from St George’s Hospital Medical School in London presented the ACTA study results: the largest ever study of cryptococcal meningitis. 678 evaluable patients from 9 sites in 4 African countries were randomized into an all oral regimen of fluconazole (1200mg/d) and flycytosine (100mg/d), amphotericin B deoxycholate (AmB) (1mg/Kg) for 7 or 14 days with either fluconazole or flucytosine.
Diabetes mellitus + new sinusitis = red flag for mucormycosis – highlighted by 418 cases in Mexico
July 20 2017
In a diabetic patient, RED FLAG warning signs of mucormycosis are: any of periorbital swelling, propotosis, sinus pain, diplopia or cranial nerve palsy, visual impairment or an ulcer on the palate, emphasise Dora Corza-Leon and colleagues from Mexico.
Deep dermatophytosis in immunocompromised patients is distinct from Majocchi’s granuloma
July 17 2017
Dermatophytes usually inhabit keratinised tissue and hardly affect the dermis. Deep dermatophytosis in the dermis has recently been described, without invasion through the hair follicle, by Ruben Kershenovich and colleagues from Petach Tikva, Israel.
Low atovaqone levels compromise prophylactic efficacy for PCP
July 10 2017
Atovaquone is one of the alternative drugs that can be used for prophylaxis against Pneumocystis pneumonia (PCP) in immunosuppressed individuals. These alternative regimens though less efficacious than cotrimoxazole (cotrim, Septrin®, Bactrim®, TMP/SMX) which is the gold standard, may be required in a significant number of patients, because of allergy or intolerance.